Lantheus Holdings, Inc. (LNTH) on Decifer Markets
Decifer Markets ranks LNTH number 181 of 276 tracked names on durable business quality.
Why it ranks here
- It keeps about 23 cents of every sales dollar as cash, safer than 87 in 100 companies we measure.
- It earns about 12% a year on the money put into the business, better than 62 in 100 companies we measure.
- It costs about 25 times its yearly profit; the middle of its industry is 14. Cheaper than 18 in 100 companies we measure, against their own industries.
- It makes about 42 cents of gross profit a year on each dollar of assets, more than 75 in 100 companies we measure.
- Its share count fell about 4.5% over the last year. On not spreading the company over more shares it stands ahead of 89 in 100 companies we measure.
- Its assets grew about 12% over the last year. On keeping expansion modest it stands ahead of 35 in 100 companies we measure.
- Its share price rose about 90% over the past year, leaving out the latest month. Stronger than 92 in 100 companies we measure.
The current read
The evidence on LNTH lines up on the supportive side: a live market force supports this name through its theme connection. The independent signals we track are telling the same story.
Themes
- Genomic Medicine & Precision Diagnostics: The collapsing cost of DNA/RNA sequencing and validation of genomic classifiers is moving clinical practice toward routine molecular diagnostics and companion testing.
Read the full LNTH research brief · See all quality rankings
Intelligence data powered by Decifer. Not financial advice. For informational purposes only.